Deuterium Capital Management LLC Takes $531,000 Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

Deuterium Capital Management LLC bought a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the first quarter, Holdings Channel.com reports. The fund bought 12,572 shares of the biotechnology company’s stock, valued at approximately $531,000. Cerevel Therapeutics makes up 1.0% of Deuterium Capital Management LLC’s holdings, making the stock its 19th biggest holding.

Other hedge funds have also recently added to or reduced their stakes in the company. Graham Capital Management L.P. raised its position in shares of Cerevel Therapeutics by 304.6% during the 3rd quarter. Graham Capital Management L.P. now owns 41,850 shares of the biotechnology company’s stock worth $914,000 after acquiring an additional 31,506 shares in the last quarter. Hudson Bay Capital Management LP acquired a new stake in Cerevel Therapeutics during the third quarter worth approximately $1,092,000. Versor Investments LP purchased a new stake in shares of Cerevel Therapeutics during the 4th quarter worth approximately $4,607,000. Calamos Advisors LLC acquired a new position in shares of Cerevel Therapeutics in the 4th quarter valued at $12,945,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Cerevel Therapeutics by 25.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 649,333 shares of the biotechnology company’s stock valued at $27,532,000 after buying an additional 132,089 shares during the last quarter. Institutional investors and hedge funds own 87.73% of the company’s stock.

Insider Buying and Selling at Cerevel Therapeutics

In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the transaction, the director now directly owns 25,928 shares of the company’s stock, valued at approximately $1,067,715.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is owned by company insiders.

Cerevel Therapeutics Stock Down 1.8 %

NASDAQ:CERE traded down $0.74 during midday trading on Friday, hitting $40.31. 976,148 shares of the company were exchanged, compared to its average volume of 1,542,042. The company has a current ratio of 10.22, a quick ratio of 10.22 and a debt-to-equity ratio of 0.60. Cerevel Therapeutics Holdings, Inc. has a fifty-two week low of $19.59 and a fifty-two week high of $43.59. The company has a market capitalization of $7.34 billion, a PE ratio of -14.77 and a beta of 1.40. The company has a fifty day simple moving average of $41.20 and a 200 day simple moving average of $41.78.

Cerevel Therapeutics (NASDAQ:CERE) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.12). As a group, equities analysts anticipate that Cerevel Therapeutics Holdings, Inc. will post -2.59 earnings per share for the current fiscal year.

About Cerevel Therapeutics

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.